Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fosheim, G. E. Articles by Limbago, B. M. Search for Related Content PubMed PubMed Citation Articles by Fosheim, G. E. Articles by Limbago, B. M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2007, p. 1611-1613, Vol. 45, No. 5
0095-1137/07/$08.00+0     doi:10.1128/JCM.02556-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Evaluation of the AdvanDx VRE EVIGENE Assay for Detection of vanA in Vancomycin-Resistant Staphylococcus aureus

G. E. Fosheim, R. B. Carey, and B. M. Limbago^*

Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd., MS C-16, Atlanta, Georgia 30333

Received 20 December 2006/ Returned for modification 13 February 2007/ Accepted 22 February 2007

Top ABSTRACT TEXT REFERENCES

 
AdvanDx VRE EVIGENE, a commercial vanA/vanB DNA hybridization assay to identify vancomycin-resistant enterococci (VRE), was evaluated for the detection of vanA in Staphylococcus aureus. Performance was assessed using S. aureus, VRE, and vancomycin-intermediate and -susceptible isolates. The assay demonstrated 100% sensitivity and specificity when analyzed visually and by optical density.

Top ABSTRACT TEXT REFERENCES

 
Vancomycin continues to be an important antimicrobial agent for the treatment of methicillin-resistant Staphylococcus aureus infections and for empirical therapy of staphylococcal infections in areas where methicillin-resistant S. aureus prevalence is high (3, 8). The widespread use of vancomycin has led to the emergence of S. aureus with reduced susceptibility to vancomycin. Vancomycin-intermediate S. aureus (VISA), for which the vancomycin MICs are 4 to 8 µg/ml (5), have been reported worldwide (15). The VISA phenotype, associated with a marked thickening of the cell wall, is not mediated by van genes, and the specific genetic mechanisms are not well understood (6). A less frequent but more concerning phenomenon involves the six vancomycin-resistant S. aureus (VRSA) isolates, for which the vancomycin MICs are 16 µg/ml (5), observed in the United States (3, 13, 16-18). All six VRSA isolates carry the vanA resistance determinant, most likely acquired from coinfecting strains of vancomycin-resistant enterococci (VRE) (4, 17, 18).

Rapid identification of VRSA is important for directing appropriate therapy for infected patients and for proper implementation of infection control measures to prevent transmission. The VRE EVIGENE Detection assay (AdvanDx, Woburn, MA) has been evaluated previously for its ability to detect vanA and vanB genes in VRE (11). In this study, we evaluated the ability of the VRE EVIGENE assay to detect vanA in S. aureus. Our evaluation included the six independent VRSA isolates described to date as well as a variant of VRSA 3 (VRSA 3b) isolated from the same patient (17). The resistant phenotype of VRSA 3b is stable (vancomycin MIC of 256 µg/ml), while the vancomycin-resistant phenotype of VRSA 3a is unstable, resulting in a susceptible phenotype in the absence of vancomycin selection (17). The seven VRE isolates associated with the VRSA cases were also tested, as these isolates are the most likely donor organisms for the vanA gene (9, 17, 18). Only one isolate, VRSA 2, did not have an associated VRE. Other organisms evaluated included six VRE with different vancomycin resistance determinants (vanC to vanG), five geographically distinct VISA isolates, two vancomycin-susceptible S. aureus isolates, and one vancomycin-susceptible Enterococcus faecalis isolate (Table 1). Isolates were identified using standard biochemical methods (1). All isolates had been previously characterized for vancomycin resistance by reference broth microdilution (5) and for the presence of the van genes by PCR (7).

View this table: [in this window] [in a new window]

TABLE 1. Evaluation of AdvanDx VRE EVIGENE assay

All isolates evaluated in this study were grown overnight on nonselective trypticase soy agar containing 5% defibrinated sheep blood (Becton Dickinson, Sparks, MD) at 35°C. Isolates were tested according to the manufacturer's protocol by using the included assay reagents provided in drop-dispensing bottles in an enzyme-linked immunosorbent assay microtiter format with both visual and spectrophotometric interpretation criteria. Wells with no color change or exhibiting a faint pink color were considered negative, while dark pink to red wells were positive. For comparison, optical density (A₄₉₀ of 0.35 is positive) was also measured with a microplate reader (Wallac1420 Victor²; Perkin-Elmer, Boston, MA).

Positive controls included E. faecalis strains carrying vanA, vanB-1, and vanB-2. VRE carrying vanC to vanG alleles and vancomycin-susceptible S. aureus and E. faecalis strains were included as negative controls (Table 1). All testing was performed in triplicate.

The VRE EVIGENE assay demonstrated 100% sensitivity and specificity (n = 31) for the detection of vanA in S. aureus and vanA or vanB in enterococci by both visual interpretation and optical density measurements (A₄₉₀). VRSA and VRE containing vanA and VRE containing vanB determinants were positive by both interpretation methods. VRE carrying van alleles vanC-1, vanC-2, vanD-3, vanD-5, vanE, and vanG were negative, as were the vancomycin-susceptible isolates. VISA isolates (n = 5) were also negative with the VRE EVIGENE assay, as expected (6) (Table 1).

One limitation of this study is the small number of VRSA isolates, all of which were vanA positive. No vanB-positive S. aureus isolates have been described to date, and therefore, the ability of the VRE EVIGENE assay to detect vanB in S. aureus could not be assessed. Additionally, interpretation of results based solely on a visual color change observation is subjective and could lead to indeterminate results that would require additional testing, although this phenomenon was not observed in our evaluation.

Nevertheless, the VRE EVIGENE assay reliably and accurately detects vanA in S. aureus isolates. The assay is easy to perform, requiring approximately 15 min of hands-on time, with a 4-h turnaround time. The assay is not yet approved by the Food and Drug Administration for detecting vanA or vanB in enterococci or for detecting vanA in S. aureus, but the VRE EVIGENE assay may be a useful nondiagnostic method for reference laboratories to further evaluate isolates with elevated vancomycin MICs.

 
We are grateful to Nancye Clark for providing the Enterococcus control strains and to AdvanDx for providing the AVE test kits.

The findings and conclusions in this document are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

 
* Corresponding author. Mailing address: Centers for Disease Control and Prevention, MS C16, 1600 Clifton Rd., Atlanta, GA 30333. Phone: (404) 639-2162. Fax: (404) 639-3822. E-mail: BLimbago{at}cdc.gov

Published ahead of print on 7 March 2007.

Top ABSTRACT TEXT REFERENCES

 

1
1. Bannerman, T. L. 2003. Staphylococcus, Micrococcus and other catalase-positive cocci that grow aerobically, p. 384-404. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed., vol. 1. ASM Press, Washington, DC.
2
2. Boyd, D. A., P. Kibsey, D. Roscoe, and M. R. Mulvey. 2004. Enterococcus faecium N03-0072 carries a new vanD-type vancomycin resistance determinant: characterization of the vanD5 operon. J. Antimicrob. Chemother. 54:680-683.[Abstract/Free Full Text]
3
3. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.[Free Full Text]
4
4. Clark, N. C., L. M. Weigel, J. B. Patel, and F. C. Tenover. 2005. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob. Agents Chemother. 49:470-472.[Abstract/Free Full Text]
5
5. Clinical and Laboratory Standards Institute/NCCLS. 2006. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. M100-S16. CLSI, Wayne, PA.
6
6. Cui, L., J. Q. Lian, H. M. Neoh, E. Reyes, and K. Hiramatsu. 2005. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3404-3413.[Abstract/Free Full Text]
7
7. Depardieu, F., B. Perichon, and P. Courvalin. 2004. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J. Clin. Microbiol. 42:5857-5860.[Abstract/Free Full Text]
8
8. Eliopoulos, G. M. 2005. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur. J. Clin. Microbiol. Infect. Dis. 24:826-831.[CrossRef][Medline]
9
9. Flannagan, S. E., J. W. Chow, S. M. Donabedian, W. J. Brown, M. B. Perri, M. J. Zervos, Y. Ozawa, and D. B. Clewell. 2003. Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype. Antimicrob. Agents Chemother. 47:3954-3959.[Abstract/Free Full Text]
10
10. Gold, H. S., S. Unal, E. Cercenado, C. Thauvin-Eliopoulos, G. M. Eliopoulos, C. B. Wennersten, and R. C. Moellering, Jr. 1993. A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob. Agents Chemother. 37:1604-1609.[Abstract/Free Full Text]
11
11. Kilic, A., M. Baysallar, G. Bahar, A. Kucukkaraaslan, F. Cilli, and L. Doganci. 2005. Evaluation of the EVIGENE VRE detection kit for detection of vanA and vanB genes in vancomycin-resistant enterococci. J. Med. Microbiol. 54:347-350.[Abstract/Free Full Text]
12
12. Patel, R., J. R. Uhl, P. Kohner, M. K. Hopkins, J. M. Steckelberg, B. Kline, and F. R. Cockerill III. 1998. DNA sequence variation within vanA, vanB, vanC-1, and vanC-2/3 genes of clinical Enterococcus isolates. Antimicrob. Agents Chemother. 42:202-205.[Abstract/Free Full Text]
13
13. Rudrik, J. T. 3 March 2005, posting date. Michigan Department of Community Health. http://www.michigan.gov/documents/VRSA_Feb05_HAN_118391_7.pdf.
14
14. Shlaes, D. M., A. Bouvet, C. Devine, J. H. Shlaes, S. al-Obeid, and R. Williamson. 1989. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob. Agents Chemother. 33:198-203.[Abstract/Free Full Text]
15
15. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, W. R. Jarvis, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.[Abstract/Free Full Text]
16
16. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.[Abstract/Free Full Text]
17
17. Weigel, L. M., R. M. Donlan, D. H. Shin, B. Jensen, N. C. Clark, L. K. McDougal, W. Zhu, K. A. Musser, J. Thompson, D. Kohlerschmidt, N. Dumas, R. J. Limberger, and J. B. Patel. 2007. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob. Agents Chemother. 51:231-238.[Abstract/Free Full Text]
18
18. Zhu, W., L. M. Weigel, N. C. Clark, L. K. McDougal, and J. B. Patel. 2006. Characterization of three Michigan vancomycin-resistant Staphylococcus aureus and vanA plasmids from associated vancomycin-resistant enterococcus. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C2-608.

---

Journal of Clinical Microbiology, May 2007, p. 1611-1613, Vol. 45, No. 5
0095-1137/07/$08.00+0     doi:10.1128/JCM.02556-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fosheim, G. E. Articles by Limbago, B. M. Search for Related Content PubMed PubMed Citation Articles by Fosheim, G. E. Articles by Limbago, B. M.